Find Clinical Trials

On this page, you will find different kinds of study results:

• A Lay summary which is a summary of clinical trial results written in an easy-to-understand way.
• A summary of results called synopsis which is written in scientific language. It is prepared for Medicines Agencies and Ethics Committees,
• A scientific publication which presents results for scientists and medical doctors.

219 Results

Protocol Code	Study Title	Active substance/Medical device	Study Phase	Therapeutic Area
CL3-06593-006	Efficacy and safety of fixed-dose combination Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine…	AMLODIPINE, INDAPAMIDE, PERINDOPRIL ARGININE, S006593	Phase 3	Cardiovascular Diseases
CL3-06593-005	Evaluation of the clinical efficacy and safety of Perindopril / Indapamide / Amlodipine fixed-dose combination…	AMLODIPINE, INDAPAMIDE, PERINDOPRIL ARGININE, S006593	Phase 3	Cardiovascular Diseases
CL3-06490-003	Efficacy on systolic and diastolic blood pressure decrease and safety of once-a-day oral 5 mg…	PERINDOPRIL ARGININE, S006490	Phase 3	Cardiovascular Diseases
CL3-05985-018	Perindopril arginine/Amlodipine versus Valsartan/Amlodipine antihypertensive strategies: Efficacy and safety in mild to moderate hypertensive patients.A…	AMLODIPINE, PERINDOPRIL ARGININE, S005985	Phase 3	Cardiovascular Diseases
CL3-05985-017	Efficacy and safety of the fixed oral perindopril arginine 5 mg/ amlopidine 5 mg combination…	AMLODIPINE, PERINDOPRIL ARGININE, S005985	Phase 3	Cardiovascular Diseases
CL3-05985-016	Efficacy and safety of the fixed oral perindopril arginine 5mg/amlodipine 5mg combination compared with amlodipine…	AMLODIPINE, PERINDOPRIL ARGININE, S005985	Phase 3	Cardiovascular Diseases
CL3-05985-006	Perindopril Amlodipine Regimen versus AT1-Receptor Blocker/thiazide: a comparison of Blood pressure Lowering: Efficacy and Safety.…	AMLODIPINE, PERINDOPRIL ARGININE, S005985	Phase 3	Cardiovascular Diseases
CL3-05702-014	Efficacy and safety of gliclazide MR (30 to 120 mg per day) associated or not…	GLICLAZIDE, S005702	Phase 3	Metabolism
CL3-05702-013	Long term double blind comparison of gliclazide MR (30 to 120 mg daily per os)…	GLICLAZIDE, S005702	Phase 3	Metabolism
CL3-05682-108	Clinical acceptability study of micronized purified flavonoid fraction 1000 mg tablets and micronized purified flavonoid…	MICRONISED PURIFIED FLAVONOID FRACTION, S005682	Phase 3	Cardiovascular Diseases
CL3-05682-107	Clinical acceptability study of micronized purified flavonoid fraction 1000 mg, one tablet per day compared…	MICRONISED PURIFIED FLAVONOID FRACTION, S005682	Phase 3	Cardiovascular Diseases
CL3-05682-105	Clinical non-inferiority study between Daflon 1000 mg, one oral suspension in a sachet per day…	MICRONISED PURIFIED FLAVONOID FRACTION, S005682	Phase 3	Cardiovascular Diseases
CL3-05590-022	Efficacy of perindopril/indapamide combination on coronary Pet Scan parameters. A 6 month, open non controlled…	INDAPAMIDE, PERINDOPRIL TERT BUTYLAMINE, S005590	Phase 3	Cardiovascular Diseases
CL3-05590-013	A factorial randomised trial of blood pressure lowering with a fixed low-dose perindopril-indapamide combination and…	GLICLAZIDE, INDAPAMIDE, PERINDOPRIL TERT BUTYLAMINE, S005590, S005702	Phase 3	Cardiovascular Diseases
CL3-05520-006	Safety and efficacy of fixed dose combination of Indapamide SR 1.5 mg / Amlodipine versus…	AMLODIPINE, INDAPAMIDE, S005520	Phase 3	Cardiovascular Diseases
CL3-05520-005	Safety and efficacy of fixed dose combination of Indapamide SR / Amlodipine in single-pill versus…	AMLODIPINE, INDAPAMIDE, S005520	Phase 3	Cardiovascular Diseases
CL3-05153-006	Efficacy and Safety of Fixed-Dose Combination atorvastatin/amlodipine/perindopril versus Fixed-Dose Combination of atorvastatin/ amlodipine in Patients…	AMLODIPINE, ATORVASTATIN, PERINDOPRIL ARGININE, S005153	Phase 3	Cardiovascular Diseases
CL3-04200-006	Early treatment of Idiopathic Parkinson’s Disease (IPD) with dopaminergic agonist piribedil in monotherapy (adaptation of…	PIRIBEDIL, S004200	Phase 3	Neuropsychiatric Diseases
CL3-01574-237	Efficacy and safety of tianeptine oral administration (25 to 50 mg/day) in elderly patients suffering…	TIANEPTINE, S001574	Phase 3	Neuropsychiatric Diseases
CL3-00780-150	International follow-up study, after the investigational drug exposure in diabetic patients previously included in the…	BENFLUOREX, S000780	Phase 3	Metabolism
CL3-00780-148	A one-year multicentre, international, randomised, double-blind study with comparison of benfluorex (150 mg od to…	BENFLUOREX, S000780	Phase 3	Metabolism
CL2-RTCCAR-001	Assessment of Active Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa) plasma kinetics in Patients at acute stage of…	RTCCAR	Phase 2	Cardiovascular Diseases
CL2-NEURO-005	Effect of Memantine 20 mg (Ebixa) and Donepezil 5 mg (Aricept) on motor cortex plasticity…	DONEPEZIL, MEMANTINE	Phase 2	Neuropsychiatric Diseases
CL2-DIABE-001	Assessment of blood glucose profile in type 2 diabetic patients after a one-week treatment with…	GLICLAZIDE	Phase 2	Metabolism
CL2-95005-003	Open-label multicentre confirmatory study of efficacy and safety of S 95005 (TAS-102) in patients with…	TIPIRACIL, TRIFLURIDINE, S095005	Phase 2	Cancers

Previous 1 2 … 5 6 7 8 9 Next